Although randomized controlled trials investigating the safety and efficacy of evolocumab (7) and alirocumab (8) do not indicate an increased incidence of diabetes compared to the standard therapy group, a recent meta-analysis has described a modest but significant increase in glycemia and glycated hemoglobin in patients treated with anti-PCSK9 mAb, with no increase in the incidence of diabetes (9). Here, PCSK9 is linked to diabetes mellitus.